stern Russia A. Chechulova1; S. Kapustin2; V. Soroka1; V. Soldatenkov2; L. Papayan2; M. GalchenkoPetersburg, Russian Federation; 2Dzhanelidze Research Institute of Emergency Medicine, Saint Petersburg, Russian Federation Background: Vitamin K plays a crucial function in hemostasis by activating each procoagulant (FII, VII, IX, X) and anticoagulant (proteins C, S, Z) components. Vitamin K-epoxide reductase 1 (VKORC1) G-1639A gene polymorphism is recognized to affect an enzyme activity and bioavailability of vitamin K. To date, there is a small data on the function of VKORC1 G-1639A variation in venous thromboembolism (VTE) development, in unique, in patients with inherited thrombophilia. Aims: To assess impact with the VKORC1 G-1639A gene polymorphism on the danger of VTE improvement in patients from North-Western Russia. Approaches: We included 600 VTE individuals (294 guys and 306 ladies, imply age 43.65.3 years) originated from the North-Western region of Russia in the study. The manage group (CG) consisted ofDzhanelidze Research Institute of Emergency Medicine, St. Petersburg,Russian Federation; 2Russian Study Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation; 3Saint Petersburg State Agrarian University, St. Petersburg, Russian Federation Background: Element XII (FXII, Hageman aspect) is involved in initiation of internal blood coagulation pathway, regulation of fibrinolysis and kallikrein-kinin program. The FXII 46 C/T gene polymorphism is associated with decrease of both level and activity of this aspect. Part of the FXII 46 C/T polymorphism in venous thromboembolism (VTE) development continues to be not clear.ABSTRACT843 of|Aims: To evaluate the function from the FXII 46 C/T gene polymorphism in VTE development in JAK2 Inhibitor custom synthesis sufferers in the North-Western Russia. Procedures: We examined 600 patients (294 men and 306 women, mean age – 43.65.3 years) with VTE. In 400 patients, the first episode of VTE was diagnosed at young age (45 years or less). Other 200 individuals composed the group with late-onset VTE. The control group (CG) consisted of 200 age- and sex-matched healthy persons. All people originated from the North-Western Russia and gave informed consent for participation in the study. Genotyping for the FXII 46 C/T polymorphism was performed by PCR-RFLP. The differences in genotypes distribution among the groups were estimated by Fisher`s precise test. Final results: Distribution in the FXII 46 C/T variants was similar among VTE individuals and CG. Frequencies for the CC, CT and TT genotypes were 48.2 , 43.0 , eight.8 in patients, and 48.0 , 45.5 , 6.five in controls, respectively. The 46T allele was additional regularly present in individuals with late-onset VTE (58.0 vs. 48.eight in young individuals; OR = 1.five; P = 0.038). Homozygosity for the 46T allele was discovered in 24 (12.0 ) individuals with late-onset VTE and 29 (7.3 ) young patients (OR = 1.7; P = 0.066). When compared to CG, the frequency of 46TT genotype was virtually 2-fold elevated in sufferers with VTE manifested soon after 45 years old (12.0 vs. six.five , respectively; OR = two.0; P = 0.083). Conclusions: Our data suggest that the FXII 46 C/T gene polymorphism might be a doable threat issue for late-onset VTE development in patients in the North-Western Russia.acquired threat variables have been infection (28 ), surgery (9 ) and trauma (7 ). No acquired risk ERĪ² Agonist drug elements were identified in 22 (41 ) youngsters. Seizures (28 ), vomiting (22 ), fever (19 ) and headache (19 ) had been essentially the most widespread symptoms. Hemiplegia/hemiparesis (35 ),